Postpartum depression affects many new mothers, increasing suicide risk. New research shows preventive cognitive behavioral ...

The results, which come on the heels of the FDA’s approval of J&J’s esketamine nasal spray Spravato as a monotherapy for ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

(NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced two ...

A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression ...

A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug ...

Scientists at Virginia Tech are revolutionizing depression treatment by tapping into how the brain processes rewards. Their ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

The treatment has become increasingly popular, especially among older men. Here is what to keep in mind if you are ...

The US FDA has approved the first of its kind ketamine-based nasal spray which is supposed to act as a standalone therapy for ...

The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.